abstract: OBJECTIVE: The incidence of @entity715 in @entity1 with @entity1252 ( @entity1252 ) is 25 to 50-fold higher than in the general population; we aimed to define the characteristics of @entity49 ( @entity49 ) and @entity715 ( @entity715 ) to identify the @entity1 at highest risk. METHODS: The study included 219 @entity1 with recent-onset @entity1252 . At baseline, standardized medical history and laboratory tests were done. Followup visits occurred quarterly, and information about damage accrual, comorbidities, and cardiovascular risk factors was updated annually. Main outcome was development of TE after @entity1252 diagnosis. RESULTS: Thirty-five @entity1 (16%) developed TE (27 @entity49 , 8 @entity715 ) during 5.21 years of followup; incidence rate 31/1000 @entity1 -years. Most events (57%) developed within the first year of diagnosis, and 69% were not associated with @entity4555 ( @entity4555 ), determined with 1 method. @entity49 developed earlier than @entity715 (2.0 vs 57.5 mos, p = 0.02). In the multivariate analysis, variables preceding @entity49 included @entity1333 , @entity1985 , dose of @entity229 , and @entity4555 in combination with anti-RNP/Sm antibodies (p < 0.03). @entity1 with @entity715 were older (median age 44 vs 29 yrs, p = 0.04), smokers, and had @entity101 , @entity6 , @entity2299 , at least 2 traditional risk factors, @entity1985 , @entity13092 , and a higher cumulative dose of @entity229 (p < 0.05). @entity4555 in combination with anti-RNP/Sm antibodies was associated with @entity49 and improved the accuracy for predicting it. CONCLUSION: Our study suggests that in @entity1252 , @entity49 and @entity715 have different risk factors. Understanding these differences is helpful for identifying @entity1 at highest risk. The use of @entity4555 plus anti-RNP/Sm for predicting @entity49 deserves further study.

title: Venous and Arterial XXXX Events in @entity1252 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['cutaneous vasculitis']

entities_list: @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['VTE', 'venous thrombotic events']

entities_list: @entity13092 :: ('MESH:D001925', 'Disease') :: ['chronic damage']

entities_list: @entity4555 :: ('MESH:C531622', 'Disease') :: ['lupus anticoagulant', 'LAC']

entities_list: @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic syndrome']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'ATE', 'arterial thrombotic events']

answer: @entity715 :: (MESH:D013927,Disease) :: ['Thrombotic']


abstract: BACKGROUND AND STUDY AIMS: Whereas data on moderate nurse-administered @entity1875 sedation (NAPS) efficacy and safety for standard endoscopy is abundant, few reports on the use of deep sedation by endoscopy nurses during advanced endoscopy, such as @entity10747 ( @entity10747 ) and Endoscopic Ultrasound (EUS) are available and potential benefits or hazards remain unclear. The aims of this study were to investigate the efficacy of intermittent deep sedation with @entity1875 for a large cohort of advanced endoscopies and to provide data on the safety. @entity1 AND METHODS: All available data from @entity1 sedated with intermittent deep NAPS for @entity10747 , EUS or double balloon enteroscopy (DBE, since the method was implemented in May 2007 through December 2012 were included for evaluation in a retrospective case-control design. RESULTS: Data from 1899 @entity1 undergoing 1899 procedures were included for evaluation. All but one procedure were completed with intermittent deep NAPS.The mean @entity1875 dose was 397mg (SD: 232.4) and the infusion rate was 23.9mg/kg. The frequency of @entity519 was 4.3% and 20 @entity1 needed assisted ventilation (1.1%). Anesthesiologic support was requested eight times (0.4%). One @entity1 was intubated due to suspected aspiration. CONCLUSIONS: Intermittent deep NAPS for advanced endoscopies in selected @entity1 provided an almost 100% success rate. However, the rate of @entity519 , @entity551 and respiratory support was high compared with previously published data, but the method was still assessed as safe.

title: High efficacy with deep nurse-administered XXXX sedation for advanced gastroenterologic endoscopic procedures.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity10747 :: ('MESH:D012183', 'Disease') :: ['Endoscopic Retrograde Cholangiopancreatography', 'ERCP']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

answer: @entity1875 :: (MESH:D015742,Chemical) :: ['propofol']


abstract: Given that @entity1691 ( @entity1691 ) occurs in approximately 5 out of 1,000 adults of European descent and the unclear pathogenesis, the aim of the research was to further predict the molecular mechanism of this disease. The Affymetrix chip data GSE25101 were available from Gene Expression Omnibus database. First of all, differentially expressed genes (DEGs) were identified by Limma package in R. Moreover, DAVID was used to perform gene set enrichment analysis of DEGs. In addition, miRanda, miRDB, miRWalk, RNA22 and TargetScan were applied to predict microRNA-target associations. Meanwhile, STRING 9.0 was utilized to collect protein-protein interactions (PPIs) with confidence score  >0.4. Then, the PPI networks for up- and down-regulated genes were constructed, and the clustering analysis was undergone using ClusterONE. Finally, protein-domain enrichment analysis of modules was conducted using DAVID. Total 145 DEGs were identified, including 103 up-regulated and 42 down-regulated genes. These DEGs were significantly enriched in phosphorylation (p  =  1.21E-05) and positive regulation of gene expression (p  =  1.25E-03). Furthermore, one module was screened out from the up-regulated network, which contained 39 nodes and 205 edges. Moreover, the nodes in the module were significantly enriched in ribosomal protein ( @entity50844 , @entity50844 and @entity68464 , mitochondrial @entity26053 ) and proteasome ( @entity68465 , @entity64730 )-related domains. Our findings that might explore the potential pathogenesis of @entity1691 and @entity50844 , @entity68464 , @entity68465 and @entity64730 have the potential to be the biomarkers for the disease.

title: Predicting the potential XXXX -related genes utilizing bioinformatics approaches.

entities_list: @entity26053 :: ('6146', 'Gene') :: ['ribosomal protein L22']

entities_list: @entity68465 :: ('5687', 'Gene') :: ['PSMA6', 'PSMA6, proteasome subunit, alpha type 6']

entities_list: @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis', 'AS']

answer: @entity1691 :: (MESH:D013167,Disease) :: ['ankylosing spondylitis']


abstract: INTRODUCTION: The 90-day risk of @entity385 in @entity1 with @entity4905 ( @entity4905 ) is estimated at between 8% and 20%. There is little consensus as to which diagnostic strategy is most effective. This study evaluates the benefits of early transthoracic echocardiography (TTE) with carotid and transcranial Doppler ultrasound in @entity1 with @entity4905 . METHODS: Prospective study of @entity1 with @entity4905 in an emergency department setting. Demographic data, vascular risk factors, and @entity13203 ) score were analysed. @entity4905 aetiology was classified according to TOAST criteria. All @entity1 underwent early vascular studies (<72hours), including TTE, carotid ultrasound, and transcranial Doppler. Primary endpoints were recurrence of @entity64 or @entity4905 , @entity583 ( @entity583 ), or @entity204 during the first year. RESULTS: We evaluated 92 @entity1 enrolled over 24 months. Mean age was 68.3  13 years and 61% were male. The mean @entity13203 ) score was 3 points (>= 5 in 30%). The distribution of @entity4905 subtypes was as follows: 12% large-artery @entity731 ; 30% cardioembolism; 10% small-vessel occlusion; 40% undetermined cause; and 8% rare causes. Findings from the early TTE led to a change in treatment strategy in 6 @entity1 (6.5%) who displayed normal physical examination and ECG findings. At one year of follow-up, 3 @entity1 had experienced @entity64 (3.2%) and 1 @entity1 experienced @entity583 (1%); no vascular @entity204 were identified. CONCLUSIONS: In our @entity4905 @entity1 , early vascular study and detecting @entity1 with silent @entity296 may have contributed to the low rate of @entity455 recurrence.

title: Rapid diagnosis and treatment of @entity4905 results in low rates of @entity64 , XXXX and @entity204 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathy']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disease']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity4905 :: ('MESH:D002546', 'Disease') :: ['transient ischaemic attack', 'TIA']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['vascular death', 'deaths']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['cerebral infarction']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: INTRODUCTION: Most visits to the primary care center are for @entity281 and particularly respiratory tract @entity281 . Antimicrobial administration for these clinical processes is common and these agents are often used to treat @entity1800 . La Fundaci  n para el Estudio de la Infecci  n (Foundation for the Study of Infection) designed the @entity1193 (D  a de la Infecci  n Respiratoria del Adulto, Adult Respiratory Infection Day) Project to investigate and assess the impact of this problem. METHODS: The study design consisted of one-day cross sections with the participation of 720 physicians belonging to Primary Health Care Centers from the 17 Autonomic Regions of Spain, establishing a one-day cross section every three months for one year. Epidemiologic, clinical and therapeutic factors were evaluated. RESULTS: The total number of visits attended was 72 929, and 14 426 @entity1 had infectious processes (43.9%). Among these, 9145 (63.4%) had a @entity1729 . The mean age of the @entity1 was 44.6 years and 34.1% had an underlying condition. Common cold was the most frequent diagnosis. Antibiotics were prescribed in 53.2% of @entity1 . Results were compared to those of a previous study. DISCUSSION: @entity1729 in particular is frequently attended in primary care. Antibiotics are widely used in our setting and self-medication is common.

title: [ @entity1729 outside the hospital. XXXX study].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1800 :: ('MESH:D014777', 'Disease') :: ['viral infections']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['Infection in general and respiratory infection', 'respiratory infection']

answer: @entity1193 :: (3557,Gene) :: ['DIRA']


abstract: OBJECTIVES: To compare the effects of @entity400 versus continuous infusion for epidural labor @entity1337 on maternal temperature and serum @entity650 ( @entity650 ) level. METHODS: This randomized trial was performed in Nanjing Maternity and @entity1 Health Care Hospital, Nanjing, Jiangsu Province, China between October 2012 and February 2014. Either @entity400 ( @entity400 , n=66) or continuous infusion (CI, n=66) was used for epidural labor @entity1337 . A bolus dose (10 ml of 0.08% @entity1342 + 0.4 ug  ml-1 @entity681 ) was manually administrated once an hour in the @entity400 group, whereas the same solution was continuously infused at a constant rate of 10 ml  @entity7285 in the CI group. Maternal tympanic temperature and serum @entity650 level were measured hourly from baseline to one hour post partum. The incidences of @entity221 (>/=38 degree celsius ) were calculated. RESULTS: The incidence of maternal @entity221 was similar between the 2 groups. There was a rising trend in mean temperature over time in both groups, but no statistical difference was detected between the groups at respective time points; maternal serum @entity650 showed similar changes. CONCLUSION: Compared with continuous infusion, @entity400 presents with the same incidence of maternal @entity221 for epidural labor @entity1337 . @entity650 elevation could be involved in mean maternal temperature increase.

title: Regular intermittent bolus provides similar incidence of maternal @entity221 compared with continuous infusion during epidural labor XXXX .

entities_list: @entity681 :: ('MESH:D017409', 'Chemical') :: ['sufentanil']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity1342 :: ('MESH:C037663', 'Chemical') :: ['ropivacaine']

entities_list: @entity400 :: ('MESH:D014202', 'Disease') :: ['regular intermittent bolus', 'RIB']

answer: @entity1337 :: (MESH:D000699,Disease) :: ['analgesia']


abstract: A 47-year-old @entity1 was admitted to hospital with complaint of general fatigue. Shortly before the admission a suspected @entity3883 was diagnosed at a local hospital. On admission, the physical examination was significant for @entity1087 ; total @entity648 was 6.43 mg/dl. The @entity5 marker CA19-9 was 2056 U/ml. Endoscopic retrograde cholangiopancreatography (ERCP) was performed and showed dilatation of common bile duct and main pancreatic duct, accompanied with an endoscopic naso-biliary drainage (ENBD) in order to reduce the @entity1087 . The duodenoscopy showed @entity85 . @entity2421 duodenography showed a filling defect at the medial side of the second portion of the duodenum. Ultrasonography (US) showed a @entity75 , sized 15 mm in diameter, at the pancreas head with dilatation of biliary tract and main pancreatic duct. An abdominal enhanced CT scan showed a mass sized 15 mm at the lower edge of the common bile duct. A selective hepatic arteriography showed no special finding. We performed a pancreatoduodenectomy with dissection of the lymph nodes. The @entity5 , sized 22x15x20 mm, was white colored and solid on the papilla. Histopathological inspection of the specimen showed an @entity1358 of the bile duct in the papilla. The @entity5 was found to infiltrate the neighboring pancreas and to contain @entity3 in lymph nodes in the hepatoduodenal ligament, post pancreaticoduodenal and para-aortic lymph nodes. This is the first report on a case of @entity1962 of the papilla major.

title: XXXX arising from the papilla major.

entities_list: @entity3883 :: ('MESH:D041781', 'Disease') :: ['obstructive jaundice']

entities_list: @entity1962 :: ('MESH:D018196', 'Disease') :: ['adenosquamous carcinoma']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['hyperechoic lesion']

entities_list: @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['adenosquamous cell carcinoma']

entities_list: @entity2421 :: ('MESH:D009123', 'Disease') :: ['Hypotonic']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['enlarged and deformed papilla']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['Adenosquamous cell carcinoma']


abstract: UNASSIGNED: @entity1313 cells invade adjacent normal brain along white matter (WM) bundles of axons. We therefore hypothesized that the location of @entity5 intersecting WM tracts would be associated with differing survival. This study introduces a method, voxel-wise survival analysis (VSA), to determine the relationship between the location of @entity1313 intersecting WM tracts and @entity1 prognosis. 113 @entity463 ( @entity463 ) @entity1 were retrospectively analyzed for this study. @entity1 specific @entity5 location, defined by contrast-enhancement, was combined with diffusion tensor imaging derived tractography to determine the location of axons intersecting @entity5 enhancement (AXITEs). VSA was then used to determine the relationship between the AXITE location and @entity1 survival. @entity5 intersecting the right anterior thalamic radiation (ATR), @entity75 (IFOF), right and left cortico-spinal tract (CST), and corpus callosum (CC) were associated with decreased overall survival. @entity5 intersecting the CST, body of the CC, right ATR, posterior IFOF, and @entity75 are associated with decreased progression-free survival (PFS), while @entity5 intersecting the right genu of the CC and anterior IFOF are associated with increased PFS. @entity1 with @entity5 intersecting the ATR, IFOF, CST, or CC had significantly improved survival prognosis if they were additionally treated with bevacizumab. This study demonstrates the usefulness of VSA by locating AXITEs associated with poor prognosis in @entity463 @entity1 . This information should be included in @entity1 -physician conversations, therapeutic strategy, and clinical trial design.

title: Location of @entity1313 intersecting white matter tracts predicts XXXX prognosis.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Patient']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumor', 'Brain tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumors', 'tumors']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['inferior longitudinal fasciculus', 'right inferior fronto-occipital fasciculus']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['GBM', 'primary glioblastoma']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: PURPOSE: To assess longer-term patterns of @entity726 medication adherence and identify whether patterns established during the first year of medication use persist during 3 subsequent years of follow-up. DESIGN: Retrospective, longitudinal cohort analysis. @entity1 : Beneficiaries aged >= 40 years who were enrolled in a United States (US)-managed care plan for >= 7 years between 2001 and 2012 and newly diagnosed and treated for @entity1538 . METHODS: For each enrollee, we quantified medication adherence using the medication possession ratio. Group-based trajectory modeling (GBTM) was applied to identify patterns of adherence for 1 and 4 years of follow-up. The percent of beneficiaries who remained in the same trajectory group in the 1- and 4-year models was tabulated to evaluate group stability. Factors impacting adherence at 1 and 4 years were identified using regression analyses. MAIN OUTCOME MEASURES: Patterns of @entity726 medication adherence. RESULTS: Of the 1234 eligible beneficiaries, GBTM identified 5 distinct @entity726 medication adherence patterns in both the 1-year and 4-year follow-up periods. These groups were as follows: (1) never adherent after their index prescription fill (7.5% and 15.6% of @entity1 in the 1- and 4-year models, respectively); (2) persistently very poor adherence (14.9% and 23.4% of @entity1 in the 1- and 4-year models, respectively); (3) declining adherence (9.5% and 9.1% of @entity1 in the 1- and 4-year models, respectively); (4) persistently moderate adherence (48.1% and 37.0% of @entity1 in the 1- and 4-year models, respectively); and (5) persistently good adherence (20.0% and 15.0% of @entity1 in the 1- and 4-year models, respectively). More than 90% of beneficiaries in the 4 groups with the worst and best adherence patterns (groups 1, 2, 3, 5) maintained their patterns from their first year throughout their 4 years of follow-up. Those with persistently moderate adherence (group 4), the largest group, were most likely to change groups from 1 to 4 years of follow-up. @entity1 with the best adherence over 4 years were more likely to be white, to be older, to earn > 60 000/year, and to have more eye care visits (P < 0.05 for all comparisons). Those with a higher initial copayment cost had lower adherence rates (b  =  -0.06/dollar, P  = 0.03). CONCLUSIONS: For most @entity1 who were newly prescribed @entity726 medications, adherence patterns observed in the first year of treatment reflect adherence patterns over the subsequent 3 years. Investing resources in both identifying and helping @entity1 with suboptimal adherence patterns over the first year may have a large impact on longer-term adherence.

title: Patterns of XXXX Medication Adherence over Four Years of Follow-Up.

entities_list: @entity1 :: ('9606', 'Species') :: ['Persons', 'patients', 'PARTICIPANTS', 'persons']

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

answer: @entity726 :: (MESH:D005901,Disease) :: ['Glaucoma']


abstract: UNASSIGNED: To identify the distinct pattern of anatomical network reorganization in surgically refractory @entity1315 ( @entity1315 ) @entity1 using a longitudinal design. We collected longitudinal diffusion-weighted images of 19 @entity1315 @entity1 before and after anterior temporal lobectomy. @entity1 were classified as @entity410 -free (SF) or @entity5815 ( @entity5815 ) at least 1 year after surgery. We constructed whole-brain anatomical networks derived from white matter tractography and evaluated network connectivity measures by graph theoretical analysis. The reorganization trajectories of network measures in SF and @entity5815 @entity1 were investigated by two-way mixed analysis of variance, with factors "group" (SF vs @entity5815 ) and "treatment" (presurgery vs postsurgery). Widespread brain structures showed opposite reorganization trajectories in FS and @entity5815 groups (interaction effect). Most of them showed group difference before surgery and then converge after surgery, suggesting that surgery remodeled these structures into a similar status. Conversly, contralateral amygdala-planum-temporale and thalamic-parietal tracts showed higher connectivity strength in @entity5815 than in SF @entity1 after surgery, indicating maladaptive neuroplastic responses to surgery in @entity5815 @entity1 . Our findings suggest that surgical outcomes are associated not only with the preoperative pattern of anatomical connectivity, but also with connectome reconfiguration following surgery. The reorganization of contralateral temporal lobe and corticothalamic tracts may be particularly important for @entity410 control in @entity1315 .

title: Connectome Reorganization Associated With Surgical Outcome in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1315 :: ('MESH:D004833', 'Disease') :: ['MTLE', 'mesial temporal lobe epilepsy']

entities_list: @entity5815 :: ('MESH:D015673', 'Disease') :: ['nonseizure-free', 'NSF']

answer: @entity1315 :: (MESH:D004833,Disease) :: ['Temporal Lobe Epilepsy']


abstract: UNASSIGNED: Cervical @entity3298 >1.5cm in diameter is the less frequently observed criteria in @entity1 with @entity573 and it is usually found in association with other symptoms during the acute phase. Moreover, the finding of fever and @entity3298 with intense local signs of @entity32 and phlegmon is rarely seen as the initial manifestation of @entity573 . We report the case of a 7-year-old @entity1 who had @entity1600 with @entity2688 and phlegmon mimicking bacterial @entity3298 as the first presentation of @entity573 . The @entity1 had fever, @entity1600 with @entity2688 , and severe @entity10 . @entity37737 was prescribed based on the clinical diagnosis of bacterial @entity3298 . Because he remained febrile and phlogistic signs worsened, after 1 day of hospitalization, antibiotics were administrated intravenously ( @entity2756 and @entity6101 ). The computed tomography of the neck showed primary @entity166 /inflammatory process. On the fourth day, the @entity1 had @entity3384 , and treatment with @entity6101 was replaced by @entity3402 because the @entity1 was still febrile. On the ninth day, he presented non-exudative bilateral conjunctival injection. On the tenth day of @entity66 , a @entity1910 appeared on his trunk, hands and feet. @entity1 's symptoms resolved after intravenous administration of immunoglobulin (2g/kg/dose), and he was discharged 2 days later. On the 14th day, the @entity1 had lamellar desquamation of fingers. @entity573 should be considered as a differential diagnosis in @entity1 with febrile @entity1600 unresponsive to empiric antibiotics even if they have @entity2688 and phlegmon.

title: @entity1600 mimicking bacterial XXXX as the first presentation of @entity573 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'boy', 'Patient']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity2756 :: ('MESH:D002443', 'Chemical') :: ['ceftriaxone']

entities_list: @entity573 :: ('MESH:C537014', 'Disease') :: ['Kawasaki disease']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['febrile disease']

entities_list: @entity1600 :: ('MESH:D014388', 'Disease') :: ['cervical lymphadenitis']

entities_list: @entity2688 :: ('MESH:D002481', 'Disease') :: ['adjacent cellulitis']

entities_list: @entity6101 :: ('MESH:D010068', 'Chemical') :: ['oxacillin']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity3384 :: ('MESH:D002971', 'Disease') :: ['dry and scaly lips']

entities_list: @entity3298 :: ('MESH:D008199', 'Disease') :: ['adenitis', 'lymphadenitis']

entities_list: @entity3402 :: ('MESH:D002981', 'Chemical') :: ['clindamycin']

entities_list: @entity37737 :: ('MESH:D002434', 'Chemical') :: ['Cefadroxil']

answer: @entity3298 :: (MESH:D008199,Disease) :: ['adenitis']


abstract: Prostanoid generation may proceed via both isoforms of cyclooxygenase, @entity9774 and @entity4665 . @entity9774 is thought to be ubiquitously expressed, whereas @entity4665 is mostly assumed to be dynamically regulated, responding to inflammatory stimuli. The cellular localization of @entity9774 and @entity4665 in the lung, an organ with high cyclooxygenase activity, is not known. In normal @entity35 lungs the expression and localization of @entity9774 and @entity4665 were examined with immunogold- @entity575 staining and the RT-PCR technique. Quantitative image analysis of the staining intensity was performed by measuring mean gray values of digitized epipolarization images. Expression of both @entity9774 and @entity4665 was readily detectable in @entity35 lungs. @entity9774 immunoreactivity localized predominantly to bronchial epithelial cells, smooth muscle cells of large hilum veins, and (with lower expression) to alveolar macrophages and pulmonary artery endothelial cells. The most intense @entity4665 staining was noted in macrophage- and mast cell-like cells, detected in close vicinity to the bronchial epithelium and in the connective tissue surrounding the vessels. In addition, strong @entity4665 expression was found in smooth muscle cells of partially muscular vessels and large veins of the hilum. Bronchial epithelial cells displayed @entity4665 immunoreactivity with limited intensity. Alveolar macrophages and alveolar septal cells were only occasionally stained with anti- @entity4665 antibodies. Both @entity9774 and @entity4665 are constitutively expressed in several cell types of normal @entity35 lung, but display clearly different patterns of cellular localization. @entity4665 may not be related only to @entity55 , but is suggested to be implicated in regulatory processes under physiological conditions as well.

title: Cyclooxygenase isoenzyme localization and mRNA expression in XXXX lungs.

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['lung inflammation']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: @entity299 is directly associated with aging as well as progression of @entity731 . The vessels begin to stiffen with age. It is speculated that the increase in stiffness can occur as a result of either increase progression of @entity731 or possibly due to the deterioration of the elastic components of the arterial wall. Regardless of the mechanism, an increase in vessel stiffness can lead to significant increase in the pathophysiological progression of the disease. The overall objectives of this investigation were to evaluate the coronary artery obtained from cadavers in their 7th, 8th and 9th of life and characterized the level of @entity731 and to identify using special @entity2362 staining techniques the involvement of fiber disruption in @entity731 . The coronary arteries were obtained from cadaveric donors at the University of Saskatoon (average age 81.7 years, range 77-92 years of age). The arteries were fixed, sectioned and stained for routine analysis as well as with an @entity2362 staining protocol. The arteries were screened and the level of @entity731 was measured as well as thickness changes within the arteries. Digital imaging was used to capture the areas of @entity2362 disruption. The overall results suggest @entity2362 disruption occurs as the @entity731 plaque progresses. The imaging system in conjunction with @entity2362 staining allows for a very sensitive method to analyze the tissue for the progression of pathophysiological disease mechanisms.

title: The use of digital imaging technology to assess the pathogenesis of coronary atherosclerosis: the role of XXXX .

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerosis']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['Heart disease']

answer: @entity2362 :: (2006,Gene) :: ['elastin']


abstract: BACKGROUND: The relative 5-year survival rate of @entity5 is moderate at best. This study was set up to evaluate whether the improvements in diagnosis and treatment in the last decades impacted the incidence, mortality and survival of @entity5 . METHODS: Data on @entity1 with @entity5 from 1989 through 2010 were extracted from the Netherlands Cancer Registry (NCR); we examined incidence, mortality and relative survival. Furthermore, information on sex, age, @entity5 stage, histology, and treatment was taken into account. RESULTS: A total of 2737 @entity1 were included. Fifty-three percent (53%) were males and 47% were females with a significant higher proportion of early stages in @entity1 . In 2010, the incidence rate (European Standardized Rate (ESR)) of @entity5 was 0.9 per 100,000 per year. The estimated annual percentage change in incidence rate since 1989 equaled 0.6% (95%CI: -0.2-1.4). Mortality rates (ESR) decreased in @entity1 until 1997 and increased thereafter. Mortality in @entity1 remained stable at 1.5 per 100,000. Over time more @entity1 were treated by surgery and radiotherapy (p<0.001). The relative five-year survival rate equaled 69% and did not change in time. CONCLUSION: We observed no relevant changes in incidence or mortality rates in the last two decades. Despite the increased combined treatment by surgery and radiotherapy, survival did not improve. This implies an urgent need for the development of new effective treatment modalities.

title: An epidemiological evaluation of XXXX in the Netherlands (1989-2010).

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'salivary gland cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

answer: @entity5 :: (MESH:D009369,Disease) :: ['salivary gland cancer']


abstract: Maintenance electroconvulsive therapy (M-ECT) has been used to control @entity161 @entity1 for more than 50 years. In spite of this, there has been no prospective study made of this treatment. Most of the available information comprises naturalistic studies or case reports. As a result many unanswered questions concerning M-ECT remain, including its therapeutic efficacy. This pilot study was done prospectively on 11 @entity161 @entity1 suffering acute exacerbations, in order to determine the merits of M-ECT. After acute treatment, using only ECT, in 16 @entity1 , 11 were able to pass the 3-week-stabilization-period. They were identified as ECT responders and enrolled into the M-ECT study. M-ECT was started one week after the last treatment in the stabilization period using a tapering regimen, fixed interval schedule, beginning with weekly intervals for 1 month (4 treatments), then biweekly intervals for 2 months (4 treatments) and with monthly intervals thereafter. No neuroleptic drugs were used. @entity1245 were the only medications prescribed to control @entity2146 on a prn basis. The duration of the study was one year. Bilateral ECT was used throughout the study. Global Assessment of Functioning (GAF), Brief Psychiatric Rating Scale (BPRS) and the Thai Mental State Exam (TMSE) were used to measure the outcome. A total of 8 @entity1 completed the study or stayed until relapse and 3 dropped out. At the 6-month-evaluation there were no relapses. After this, however, 5 @entity1 suffered relapses. Only 3 could complete the one year study. There were no serious side effects. This study indicates that M-ECT may have a role in the maintenance of some @entity161 @entity1 . Further studies are needed to determine the optimum frequency and the role of concurrent neuroleptic use.

title: Maintenance ECT in XXXX : a pilot study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1245 :: ('MESH:D001569', 'Chemical') :: ['Benzodiazepines']

entities_list: @entity2146 :: ('MESH:D011595', 'Disease') :: ['agitation']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenic']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: A retrospective epidemiological study of @entity1 treated for @entity32364 ( @entity32364 ) during 2003-2013 at Oslo University Hospital, Rikshospitalet, was undertaken to assess its incidence, management and treatment outcomes. Out of a total of 123 @entity1 with @entity5142 (84 female, 39 @entity1 ), 38 @entity1 were diagnosed with @entity32364 , all of whom were female. Of these, 23 lived in the South-Eastern Norway Regional Health Authority, representing an incidence of 0.2 per 100,000 (95% CI 0.13-0.3) in this region of 2.9  million inhabitants. Mean age at diagnosis was 54 years (range 20-85 years), and the mean interval between symptom onset and diagnosis was 3.1 years. The 38 @entity1 with @entity32364 underwent a total of 132 operations between 2003 and 2013. All @entity1 were managed endoscopically using laser surgery, with or without @entity288 and @entity1138 , with dilatation by balloon or bougie. Eight @entity1 (21.1%) required only one procedure, while 30 @entity1 (78.9%) had multiple operations. The median follow-up for all @entity1 from the first operation was 5.3 years. The mean interval between procedures was 1  year for @entity1 aged 20-48 years, 1.3 years for @entity1 aged 49-61 years and 3.0 years for @entity1 aged 62-85 years. No clinically significant complications were observed. In conclusion, the symptoms of @entity32364 can be treated effectively with laser surgery and dilatation but the recurrence rate remains high and the time interval between operations does not increase with time, making @entity32364 a continuing challenge.

title: XXXX : an epidemiological single-center study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity1138 :: ('MESH:D016685', 'Chemical') :: ['Mitomycin C']

entities_list: @entity32364 :: ('MESH:C536283', 'Disease') :: ['ISS', 'idiopathic subglottic stenosis']

entities_list: @entity5142 :: ('MESH:D007829', 'Disease') :: ['subglottic stenosis']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity32364 :: (MESH:C536283,Disease) :: ['Idiopathic subglottic stenosis']


abstract: Previous animal studies have shown that the nature and duration of postprandial motility in the small bowel depend both on the caloric load and the chemical composition of a meal. It is not clear whether this is also true for the @entity1 small bowel. Therefore we investigated the motor activity of the @entity1 small bowel in response to nutrient liquids of different caloric value and different chemical composition. Ten @entity1 volunteers underwent three separate, 24-hr ambulatory manometry studies. They drank water, a pure @entity413 solution, and Intralipid 10% in volumes of both 300 and 600 ml. The caloric value of the nutrient liquids was 330 and 660 kcal, respectively. Records were analyzed visually for the reappearance of phase III of the MMC after ingestion of a test liquid, and a validated computer program calculated the incidence and amplitude of @entity2472 during the postprandial period. Neither duration of the postprandial interval nor the mean incidence or mean amplitude of @entity2472 were different between the fat and the @entity1735 solutions, but phase III reappeared significantly later after ingestion of the nutrient liquids than after water (P = 0.0002). Duration of the postprandial interval also depended on the volume or the caloric load of a liquid meal (P = 0.0012). Mean incidence of @entity2472 tended to be higher after ingestion of nutrient liquids than after water (P = 0.059). We conclude that in ambulant subjects, small bowel motor activity in response to chemically diverse liquid meals is remarkably uniform. This is true for the duration of the postprandial motor activity, as well as the incidence and amplitude of @entity2472 during that period. The caloric value of a liquid meal, however, regulates the duration of the postprandial interval in the @entity1 small bowel.

title: XXXX small bowel motor activity in response to liquid meals of different caloric value and different chemical composition.

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity2472 :: ('MESH:C536214', 'Disease') :: ['contractions']

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: BACKGROUND: A screening colonoscopy is recommended in first-degree relatives (FDRs) of @entity14 @entity1 ; few prospective, controlled studies have evaluated colorectal findings in a population-based screening program. OBJECTIVE: To evaluate the prevalence of @entity14 ( @entity652 and @entity420 ) in this increased-risk population, to compare it with that of average-risk individuals, and to identify features that might allow risk stratification for @entity5 among FDRs. DESIGN: Cross-sectional study. SETTING: Population-based screening program in Trentino, Italy. @entity1 : FDRs of @entity14 @entity1 between 45 and 75 years of age with no history of @entity14 or @entity29 . CONTROLS: Average-risk individuals undergoing screening colonoscopy. INTERVENTION: Screening colonoscopy. RESULTS: @entity5 was found in 33.4% of 1252 FDRs and in 30.3% of 765 controls; advanced @entity5 was found in 11.3% of FDRs and in 6.3% of controls. Odds ratios (ORs) from the multivariate logistic regression analysis adjusted for age, sex, cecal intubation rates, and colon cleansing showed an increased risk of advanced @entity5 (OR 2.41; 95% CI, 1.69-3.43; P < .0001) in FDRs. Age older than 56 years (OR 1.83; 95% CI, 1.15-2.99; P = .013) and male sex (OR 2.17; 95% CI, 1.39-3.10; P < .001) are independent predictors of advanced @entity5 . LIMITATIONS: Italian subjects living in the same geographic area; of 4301 FDRs, 2521 were excluded. CONCLUSIONS: The increased risk of advanced @entity5 supports the current recommendation for colonoscopic screening in this group; age and sex may assist in risk stratification of these individuals.

title: Colonoscopic findings in first-degree relatives of XXXX with @entity14 : a population-based screening program.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Neoplasia', 'neoplasia']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['hereditary colorectal cancer syndromes', 'colorectal neoplasia', 'colorectal cancer']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: INTRODUCTION: Hospitals are under pressure to provide care that not only shortens hospital length of stay but also reduces subsequent hospital admissions. Hospital readmissions have received increased attention in outcome reporting. The authors identified survivors of @entity1576 who then required subsequent hospitalization. A cohort of @entity1576 survivors, who participated in an early intensive care unit (ICU) mobility program, was assessed to determine if variables from the index hospitalization predict hospital readmission or @entity204 , within 12 months of hospital discharge. METHODS: Hospital database and responses to letters mailed to 280 @entity1576 survivors. Univariate predictor variables shown to be associated with hospital readmission or @entity204 (P < 0.1) were included in a multiple logistic regression. A stepwise selection procedure was used to identify significant variables (P < 0.05). RESULTS: Of the 280 survivors, 132 (47%) had at least 1 readmission or died within the first year, 126 (45%) were not readmitted and 22 (8%) were lost to follow-up. Tracheostomy [odds ratio (OR), 4.02 (95%CI, 1.72-9.40)], female gender [OR, 1.94 (95%CI, 1.13-3.32)], a higher Charlson Comorbidity Index assessed upon index hospitalization discharge [OR, 1.15 (95%CI, 1.01-1.31)] and lack of early ICU mobility therapy [OR, 1.77 (95%CI, 1.04-3.01)] predicted readmission or @entity204 in the first year postindex hospitalization. CONCLUSIONS: Tracheostomy, female gender, higher Charlson Comorbidity Index and lack of early ICU mobility were associated with readmissions or @entity204 during the first year. Although the mechanisms of increased hospital readmission are unclear, these findings may provide further support for early ICU mobility for @entity1 with @entity1576 .

title: Receiving early mobility during an intensive care unit admission is a predictor of improved outcomes in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['acute respiratory failure']

answer: @entity1576 :: (MESH:D012131,Disease) :: ['acute respiratory failure']


abstract: BACKGROUND: @entity9643 is an @entity166 caused by @entity9642 , which persists in the lung of mammals. Infection in the skin is very rare. RESULTS: A subcutaneous @entity5 with itching developed on the right lateroabdominal region of a 55-year-old @entity1 10 days after eating fresh-water crab. It was surgically excised 2 months later. Examination of a specimen of the surgically excised @entity5 revealed an abscess containing many eosinophils. Parasites or other infectious organisms were not found in sections. The blood eosinophil count of the @entity1 was elevated, and @entity9642 -specific immunoglobulin G (IgG) antibody titer was strongly detected in the serum. The @entity5 was diagnosed as @entity9643 caused by @entity9642 . Three months after eating the crab, a chest X-ray film showed a @entity1143 . P. westermani-specific IgG antibody was also detected in the pleural fluid. The @entity1 was given 75 mg/kg/day of @entity2039 for 3 days. The @entity1143 gradually disappeared after the medication. CONCLUSIONS: This @entity1 had @entity9643 with a @entity1489 that was diagnosed prior to the expression of a @entity1143 .

title: A case of @entity9643 with XXXX .

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion']

entities_list: @entity9642 :: ('34504', 'Species') :: ['Paragonimus', 'P. westermani']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['skin tumor']

entities_list: @entity9643 :: ('MESH:D010237', 'Disease') :: ['cutaneous paragonimiasis', 'Paragonimiasis']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious disease']

entities_list: @entity2039 :: ('MESH:D011223', 'Chemical') :: ['praziquantel']

answer: @entity1143 :: (MESH:D010996,Disease) :: ['pleural effusion']


abstract: When ectotherms are exposed to low temperatures, they enter a cold-induced @entity772 (chill @entity772 ) that prevents resource acquisition, mating, oviposition, and escape from predation. There is substantial variation in time taken to recover from chill @entity772 both within and among species, and this variation is correlated with habitat temperatures such that insects from cold environments recover more quickly. This suggests an adaptive response, but the mechanisms underlying variation in recovery times are unknown, making it difficult to decisively test adaptive hypotheses. We use replicated lines of @entity238 selected in the laboratory for fast (hardy) or slow (susceptible) chill- @entity772 recovery times to investigate modifications to metabolic profiles associated with cold adaptation. We measured metabolite concentrations of flies before, during, and after cold exposure using NMR spectroscopy to test the hypotheses that hardy flies maintain metabolic homeostasis better during cold exposure and recovery, and that their metabolic networks are more robust to cold-induced perturbations. The metabolites of cold-hardy flies were less cold responsive and their metabolic networks during cold exposure were more robust, supporting our hypotheses. Metabolites involved in membrane lipid synthesis, @entity2340 metabolism, oxidative stress, energy balance, and @entity1521 metabolism were altered by selection on cold tolerance. We discuss the potential significance of these alterations. This article is protected by copyright. All rights reserved.

title: Cold adaptation shapes the robustness of metabolic networks in XXXX .

entities_list: @entity1521 :: ('CHEBI:26271', 'Chemical') :: ['proline']

entities_list: @entity2340 :: ('CHEBI:27897', 'Chemical') :: ['tryptophan']

entities_list: @entity238 :: ('7227', 'Species') :: ['Drosophila melanogaster']

answer: @entity238 :: (7227,Species) :: ['Drosophila melanogaster']


abstract: UNASSIGNED: In spite of recent advances in the treatment of @entity302 , up to 35% of @entity1 living with the condition do not respond to accessible anti- @entity302 drugs (AEDs) and continue to experience regular, devastating and potentially life-threatening @entity410 . @entity528 is a significant feature of @entity302 in @entity1 and experimental models. It has been reported that @entity17657 , an endogenous ligand for the angiotensin-1-like receptor (APJ), has anticonvulsive as well as protective effects in some neurodegenerative situations. In the current study, we investigated the effects of @entity17657 -13 on @entity5093 ( @entity17202 )-induced @entity2359 in @entity35 's brain primary culture. @entity131 was induced by 20mM @entity17202 and the cells viability was examined by @entity98 assay. Intracellular @entity460 , reactive @entity26 species (ROS) and mitochondrial membrane potential were determined by fluorescence spectrophotometry methods. Markers of apoptosis were determined by immunohistochemistry. The data showed that @entity17202 caused a loss of cell viability and mitochondrial membrane potential. In addition, intracellular reactive @entity26 species, intracellular @entity460 , @entity4665 and @entity4124 positive cells were increased in @entity17202 -treated cells. Incubation of the cells with aplein-13 (10 M) elicited protective effect and reduced markers of cell damage and @entity204 . The results suggest that @entity17657 -13 has protective effects against @entity17202 -induced @entity137 and such effects are accompanied by its @entity460 blocking, antioxidant and, anti-inflammatory and anti-apoptotic properties.

title: XXXX -13 protects @entity35 primary cortical glia-neuron co-culture against @entity5093 -induced @entity137 .

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'people']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['Cell injury']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5093 :: ('MESH:D010433', 'Chemical') :: ['pentylenetetrazole']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic', 'epilepsy']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['Neuronal death']

entities_list: @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']

answer: @entity17657 :: (58812(Tax:10116),Gene) :: ['Apelin']


abstract: Exposure to high-dose radiation results in detrimental effects on survival. The effects of combined @entity130 , such as radiation in combination with @entity548 , the typical injury of victims exposed to a radiation blast, on survival and hematopoietic effects have yet to be understood. The purpose of this study was to evaluate the effects of @entity1161 ( @entity1161 ) combined with @entity548 (i.e., combined injury, CI) on survival and hematopoietic effects, and to investigate whether @entity548 ( @entity548 ) enhanced @entity1161 -induced mortality and @entity1583 . Male CD2F1 @entity19 (10 weeks old) were given one single exposure of y- radiation (60Co) at various doses (0.6 Gy/min). Within 2 hr after @entity1161 , animals under anesthesia were bled 0% (Sham) or 20% ( @entity548 ) of total blood volume via the submandibular vein. In these @entity19 , @entity548 reduced the LD50/30 for 30-day survival from 9.1 Gy ( @entity1161 ) to 8.75 Gy (CI) with a DMF of 1.046. @entity1161 resulted in @entity1431 , @entity882 , erythropenia, and bone marrow cell depletion, but decreased the @entity185 activation response. @entity1161 increased @entity635 , @entity777 , @entity636 , and @entity637 concentrations in serum, bone marrow, ileum, spleen, and kidney. Some of these adverse alterations were magnified by CI. @entity14190 production was increased in kidney and blood more after CI than @entity1161 . Furthermore, CI altered the global miRNAs expression in kidney and the ingenuity pathway analysis showed that miRNAs viz., @entity34638 , @entity29036 and miR-29b that were associated with @entity1210 and @entity32 . This study provides preliminary evidence that non-lethal @entity548 exacerbates @entity1161 -induced mortality and cell losses associated with high-dose y-radiation. We identified some of the initial changes occurring due to CI which may have facilitated in worsening the injury and hampering the recovery of animals ultimately resulting in higher mortality.

title: @entity548 Exacerbates Radiation Effects on Survival, @entity1431 , XXXX , Erythropenia, Bone Marrow Cell Depletion and Hematopoiesis, and Inflammation-Associated microRNAs Expression in Kidney.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage', 'Hemo']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombopenia']

entities_list: @entity1161 :: ('MESH:D011832', 'Disease') :: ['RI', 'radiation injury']

entities_list: @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematopoietic syndrome']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukocytopenia']

entities_list: @entity1210 :: ('MESH:C536227', 'Disease') :: ['hematopoiesis']

answer: @entity882 :: (MESH:D013921,Disease) :: ['Thrombopenia']


abstract: UNASSIGNED: In this study, we demonstrated a natural silk fibroin protein (SFP) that was blended with a Chinese herbal extract ( @entity19988 , BAI) to obtain an effective combination for producing electrospun nonwoven mats with anti-inflammatory and antibacterial functions. A series of SFP-based electrospun nonwoven mats with additives of varying compositions were produced and investigated. Performance comparisons showed that the SFP/ @entity4280 (PVP)/BAI nonwoven mat is the optimal one. In vitro, SFP/PVP/BAI nonwoven mat is effective in inhibiting the formation of @entity3542 in lipopolysaccharide (LPS)-induced @entity3542 formation in Raw 264.7 macrophages model and the growth of @entity794 ( @entity794 ). Especially in the case of SFP/PVP/BAI nonwoven mat, Bai has been proved to reach their maximum amount of releases of approximately 64.8% within 24 h of contact with water-based environment as compared to the SFP/BAI nonwoven mat (only 30.1% of release within 24 h). For in vivo experiments, a 1.2 cm * 1.2 cm wound area was created on the back of @entity19 and seeded with 1 * 10(7) CFU/mL of @entity794 to induce an infected wound model. The experimental results show significant acceleration of the wound closure process in @entity19 treated with SFP/PVP/BAI nonwoven mat (4 days of reduction as compared to the untreated group), reduction in infiltration of neutrophils, @entity3542 formation, and inhibition of growth of wound bacteria. Histological images of the group treated with SFP/PVP/BAI nonwoven mat showed a compete repair of skin hierarchy, increasing production of collagen fibers, and enhancement of angiogenesis. This may bring a better recovery of skin appearance after treatment.    2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2015.

title: Silk fibroin protein-based nonwoven mats incorporating XXXX Chinese herbal extract: preparation, characterizations, and in vivo evaluation.

entities_list: @entity19988 :: ('MESH:C006680', 'Chemical') :: ['baicalein']

entities_list: @entity3542 :: ('CHEBI:16301', 'Chemical') :: ['nitrite']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus', 'S. aureus']

entities_list: @entity4280 :: ('MESH:D011205', 'Chemical') :: ['polyvinylpyrrolidone']

answer: @entity19988 :: (MESH:C006680,Chemical) :: ['baicalein']


abstract: BACKGROUND: Green tea is known as a dietary supplement and a novel functional food worldwide. Since there are increasing preclinical evidence about efficacy of green tea for treating @entity571 , this study has aimed at assessing its efficacy and safety for @entity1 with @entity626 . METHODS: This is a randomized open-label active-controlled clinical trial. As many as fifty adults with @entity571 of knee were randomly allocated to receive the green tea extract (in dosage form of tablet) plus @entity3522 tablet as "intervention group"; or: @entity3522 tablet  alone as "control group" for a period of four weeks. @entity1 were assessed at the beginning of intervention, and then 4 weeks later, in terms of @entity158 score via visual analogue scale (VAS), and Western Ontario and McMaster Universities @entity571 Index (WOMAC) questionnaire's total score in addition to its 3 sub-scores. Furthermore, they were asked about any adverse effects during intervention period. RESULTS: Mean differences of @entity227 , total WOMAC, and WOMAC physical function scores in green tea group showed a significant reduction, compared with the control group (P  =  0.038, P  =  0.006, and P  =  0.004, respectively). However, No significant differences between the two groups were observed, regarding mean differences of WOMAC @entity158 and stiffness scores of the enrolled @entity1 (P  =  0.163, and P  =  0.150, respectively). Additionally, only 1 @entity1 reported gastric upset [in control group]. CONCLUSIONS: It seems that green tea extract might well be considered as an adjunctive treatment both for control of @entity158 and for the betterment of knee joint physical function in adults with @entity571 . However, further studies of longer duration and larger sample size are needed.

title: Green tea (Camellia sinensis) for XXXX with @entity626 : A randomized open-label active-controlled clinical trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis', 'Osteoarthritis']

entities_list: @entity3522 :: ('MESH:D004008', 'Chemical') :: ['diclofenac']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Complex III (CIII; ubiquinol @entity4674 reductase of the mitochondrial respiratory chain) catalyzes electron transfer from @entity4588 and @entity2125 -linked dehydrogenases to @entity4674 . CIII is made up of 11 subunits, of which all but one ( @entity13508 ) are encoded by nuclear DNA. @entity6345 are rare and manifest heterogeneous clinical presentations. Although pathogenic mutations in the gene encoding mitochondrial @entity13508 have been described, mutations in the nuclear-DNA-encoded subunits have not been reported. Involvement of various genes has been indicated in assembly of @entity375 CIII (refs. 8-11). So far only one such gene, @entity35506 , has been identified in @entity1 . @entity35506 represents, therefore, an obvious candidate gene in @entity6345 . Here, we report @entity35506 mutations in six @entity1 , from four unrelated families and presenting neonatal proximal @entity8 , hepatic involvement and @entity75 . Complementation study in @entity375 confirmed the deleterious effect of these mutations. Mutation of @entity35506 would seem to be a frequent cause of @entity6345 , as one-third of our @entity1 have @entity35506 mutations.

title: A mutant mitochondrial respiratory chain assembly protein causes XXXX in @entity1 with @entity8 , @entity75 and liver failure.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity2125 :: ('MESH:D009243', 'Chemical') :: ['nicotinamide adenine dinucleotide']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['tubulopathy']

entities_list: @entity4588 :: ('MESH:D019802', 'Chemical') :: ['succinate']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy']

entities_list: @entity6345 :: ('MESH:C565128', 'Disease') :: ['CIII deficiencies', 'CIII deficiency']

answer: @entity6345 :: (MESH:C565128,Disease) :: ['complex III deficiency']


abstract: UNASSIGNED: Adeno-associated viruses (AAVs) have become powerful tools in neuroscience for both basic research and potential therapeutic use. They have become especially important tools for optogenetic experiments based on their ability to achieve transgene expression in postmitotic neurons with regional selectivity. With the use of appropriate promoter elements they can achieve cellular specificity as well. One population of neurons that plays a central role in @entity1 neurodegenerative and @entity146 diseases are the @entity935 neurons of the midbrain. To study these neurons in vivo with advanced techniques it would be highly advantageous to characterize an appropriate specific promoter. To this end we have characterized a 2.5-kb sequence of the @entity35 @entity4149 hydroxylase ( @entity68883 ) promoter. The @entity68883 (2.5) promoter induced expression of the fluorescent reporter protein mCherry in SN @entity935 neurons. Although it showed excellent specificity in cortex and striatum, where no reporter expression was observed, in the SN region many neurons expressed reporter but not @entity68883 . We show that some of the @entity68883 negativity is due to the suppression of its expression by the transgene. We conclude that @entity68883 (2.5) does preferentially label @entity935 neurons but its specificity is not complete within the substantia nigra and caution must be used.

title: A quantitative evaluation of a 2.5-kb @entity35 XXXX hydroxylase promoter to target expression in ventral mesencephalic @entity935 neurons in vivo.

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

answer: @entity4149 :: (D014443,Chemical) :: ['tyrosine']


abstract: BACKGROUND: Branched-chain @entity1718 or @entity33252 have been reported to possess anti- @entity5 activity in @entity5 models. Here we study @entity70398 ( @entity70399 ), a branched-chain @entity844 , isolated from a sea @entity9688 extract, on the growth of @entity263 cells and investigate the underlying mechanisms of its effect. METHODS: 12-MTA was evaluated by @entity98 assay for its ability to inhibit cell proliferation in various @entity5 types. The ability of 12-MTA to induce apoptosis of @entity5049 cells was examined by morphologic changes, @entity2667 (PI) staining, and @entity522 activation. Furthermore, alteration of @entity9610 metabolism by 12-MTA was examined in @entity5049 and RBL-1 cells and in purified lipoxygenase (LOX) and cyclooxygenase (COX) enzymes. RESULTS: 12-MTA inhibited proliferation of various cell lines, with IC50s ranging from 17.99 to 35.44 microg/ml. PI staining clearly showed that 12-MTA caused @entity5049 cell death through induction of apoptosis. At 50 microg/ml, 12-MTA increased @entity522 activity four to seven-fold compared with that in control cells. Examination of cellular @entity3899 metabolism showed that at 25 microg/ml, 12-MTA reduced the level of @entity11902 ( @entity11902 ) by 45%. Furthermore, exogenous @entity11902 protects @entity5049 cells from 12-MTA induced cell death. CONCLUSIONS: 12-MTA inhibited proliferation of @entity5 cells via apoptosis, in which @entity522 may play a role. At relevant concentrations, 12-MTA can selectively inhibit the formation of @entity11902 , a metabolite of @entity1437 . This agent may be a novel adjunctive therapy for selected @entity5 including @entity263 .

title: Inhibition of proliferation of XXXX cells by the branched-chain @entity844 , @entity70398 , is associated with inhibition of @entity1437 .

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity2667 :: ('MESH:D011419', 'Chemical') :: ['propidium iodide']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'various tumor', 'cancer', 'malignancies']

entities_list: @entity70398 :: ('MESH:C069642', 'Chemical') :: ['12-methyltetradecanoic acid']

entities_list: @entity9610 :: ('CHEBI:23899', 'Chemical') :: ['eicosanoid']

entities_list: @entity11902 :: ('MESH:C022022', 'Chemical') :: ['5-hydroxyeicosatetraenoic acid', '5-HETE']

entities_list: @entity3899 :: ('CHEBI:32395', 'Chemical') :: ['arachidonate']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity33252 :: ('MESH:D005233', 'Chemical') :: ['fatty alcohols']

answer: @entity5049 :: (57332,Gene) :: ['PC3']


abstract: UNASSIGNED: Pregnancy-related complications such as @entity1468 and @entity600 now represent a notable burden of adverse health. @entity1468 is a @entity101 unique to pregnancy. It is an important cause of @entity204 worldwide and a leading cause of @entity1592 and iatrogenic prematurity. Fifteen million @entity1 are born preterm each year globally, but more than one million of those do not survive their first month of life. Currently there are no predictive tests available for diagnosis of these @entity14422 and the biological mechanisms of the diseases have not been fully elucidated. Mass spectrometry-based proteomics have all the necessary attributes to provide the needed breakthrough in understanding the pathophysiology of complex @entity1 diseases thorough the discovery of biomarkers. The mass spectrometry methodologies employed in the studies for @entity14422 are evaluated in this article. Top-down proteomic and peptidomic profiling by laser mass spectrometry, liquid chromatography or capillary electrophoresis coupled to mass spectrometry, and bottom-up quantitative proteomics and targeted proteomics by liquid chromatography mass spectrometry have been applied to elucidate protein biomarkers and biological mechanism of @entity14422 . The proteomes of serum, urine, amniotic fluid, cervical-vaginal fluid, placental tissue, and cytotrophoblastic cells have all been investigated. Numerous biomarkers or biomarker candidates that could distinguish complicated pregnancies from healthy controls have been proposed. Nevertheless, questions as to the clinically utility and the capacity to elucidate the pathogenesis of the @entity1468 and @entity600 remain to be answered.

title: Mass Spectrometry-Based Proteomics for @entity1468 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'infants']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive disorder']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['preterm birth']

entities_list: @entity1592 :: ('MESH:D005317', 'Disease') :: ['fetal growth restriction']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['pre-eclampsia', 'Pre-eclampsia']

entities_list: @entity14422 :: ('MESH:D011248', 'Disease') :: ['pregnancy-related complications']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['maternal death']

answer: @entity600 :: (MESH:D000014,Disease) :: ['Preterm Birth']


abstract: BACKGROUND: The @entity3003 -based chemotherapeutic regimen M-CAVI ( @entity1499 , @entity3003 , and @entity5713 ) is active against @entity150 and can be administered to @entity1 who are ineligible to receive @entity900 or @entity632 . The authors designed a randomized study to evaluate whether M-CAVI offers a therapeutic advantage over the @entity900 -based regimen M-VAC ( @entity1499 , @entity5713 , @entity632 , and @entity900 ) in the treatment of @entity1 with surgically incurable advanced @entity150 . METHODS: @entity1 with surgically incurable advanced @entity150 were enrolled on a randomized trial comparing M-CAVI, which consists of @entity3003 (300 mg/m2 on Day 2, adjusted using Calvert's formula for an area under the curve of 5), @entity1499 (30 mg/m2 on Days 1, 15, and 22), and @entity5713 (3 mg/m2 on Days 2, 15, and 22) administered every 28 days, versus standard M-VAC. The eligibility criteria included histologically proven @entity150 , surgically incurable disease, and no prior chemotherapy. @entity1 were treated until disease progression or unacceptable @entity137 occurred. RESULTS: From January 1989 to January 1994, 47 assessable @entity1 were included. Seventeen @entity1 had @entity1600 and 30 had distant metastatic disease. Twenty-three @entity1 were randomized to receive M-CAVI and 24 to receive M-VAC. @entity1 characteristics in the two groups were similar. Overall response rates were 39% (95% confidence interval [CI], 20-62%) for M-CAVI and 52% (95% CI, 30-73%) for M-VAC (P = 0.3), with 3 complete responses observed among @entity1 treated with M-VAC and none among those in the M-CAVI group. M-VAC was associated with more @entity344 , @entity3136 , @entity1665 , and Grade 4 @entity1398 than M-CAVI. One @entity137 -related @entity204 occurred in the M-VAC group. There was a statistically significant difference in median disease-related survival time favoring M-VAC (16 months; range, 6 to 22+) versus M-CAVI (9 months; range, 6 to 14+) (P = 0.03). CONCLUSIONS: M-CAVI is less toxic but less active than M-VAC in the treatment of @entity1 with advanced @entity150 . @entity3003 -based regimens in which @entity3003 is administered at the dose range used in the current study should be reserved for @entity1 who cannot tolerate @entity900 treatment. Further research is required to assess the impact of high dose @entity3003 in the treatment of this disease.

title: XXXX -based versus @entity900 -based chemotherapy in the treatment of surgically incurable advanced @entity150 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1600 :: ('MESH:D014388', 'Disease') :: ['lymph node disease']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal toxicity']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder carcinoma']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']

answer: @entity3003 :: (MESH:D016190,Chemical) :: ['Carboplatin']


abstract: AIM: Formulation and evaluation of @entity13558 , an anti- @entity5 drug loaded in different biodegradable polymeric nanoparticles. MATERIALS AND METHODS: Different carrier systems such as @entity10124 ( @entity7050 50:50), @entity7049 ( @entity1989 ) and @entity4351 (PCL) are used to prepare nanoparticles by simple emulsion technique. The surfactants @entity4832 and @entity6743 were studied for their use as stabilizing agents at varying concentrations. The formulations were studied for their particle size, zeta potential, entrapment efficiency and solid state characteristics, and also were tested for their in vitro @entity137 and in vivo behavior in @entity35 . KEY FINDINGS: The entrapment ranged from 35 to 85%, depending on the drug-polymer ratio used. Particle size ranged from 100 to 350nm with optimal zeta potential. Accordingly, discrete spherical nanoparticles with smooth surface were obtained as evidence from Field Emission Scanning Electron Microscopy (FESEM) study. The solid state characteristics revealed dispersion of drug at the molecular level in the polymeric matrix of nanoparticles. A non-Fickian transport with initial burst release followed by slow release was observed with nanoparticles. The remarkable decrease in cell viability at various time points was observed for @entity7050 nanoparticles compared to other polymer matrices. The AUC(0 >    ) of @entity7050 , @entity1989 and PCL nanoparticles were found to be 4.77, 19.31 and 19.81 fold higher than (p<0.05) @entity13558 in solution, respectively. Also, pharmacokinetics study revealed the long time circulation of @entity13558 loaded polymeric nanoparticles. SIGNIFICANCE: The results suggest that developed nanoparticles could be used successfully for effective management of @entity0 chemotherapy.

title: Nanomedicine of @entity13558 for @entity0 : Physicochemical evaluation, in vitro XXXX on BT-549 and MCF-7 cell lines and preclinical study on @entity35 model.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity4832 :: ('MESH:D011142', 'Chemical') :: ['polyvinyl alcohol']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity7049 :: ('MESH:C010506', 'Chemical') :: ['poly(lactic-acid)']

entities_list: @entity4351 :: ('CHEBI:60736', 'Chemical') :: ['poly(  -caprolactone)']

entities_list: @entity13558 :: ('MESH:C090450', 'Chemical') :: ['anastrozole']

entities_list: @entity10124 :: ('CHEBI:53493', 'Chemical') :: ['poly(lactide-co-glycolide)']

entities_list: @entity6743 :: ('MESH:D003840', 'Chemical') :: ['sodium deoxycholate']

answer: @entity137 :: (MESH:D064420,Disease) :: ['cytotoxicity']


abstract: BACKGROUND: Links between environmental chemicals and @entity1 health have emerged, but the effects on hearing were less studied. Therefore, the aim of the present study was to investigate the relationships of different sets of environmental chemicals and the hearing conditions in a national and population-based setting. METHODS: Data was retrieved from the US National Health and Nutrition Examination Surveys, 2011-2012 including demographics, serum measurements, lifestyle factors, self-reported hearing conditions, and urinary environmental chemical concentrations. Chi-square test, t test, and survey-weighted logistic regression models were performed. RESULTS: Among the American adults aged 20-69 (n   =   5560), 462 (8.3  %) @entity1 reported their hearing condition as moderate trouble to deaf. They had higher levels of urinary @entity9436 and polyfluorinated compounds but not heavy metals, @entity5600 , @entity3494 , pesticides, @entity11572 , @entity28728 , @entity13756 , @entity1507 , and @entity8875 concentrations. Also, 466 (10.0  %) @entity1 had hearing difficulties during conversation. They had higher levels of urinary @entity1953 ( @entity18704 , 95  % confidence interval (95%CI) 1.00-1.63), molybdemum (OR 1.45, 95%CI 1.04-2.02), @entity9756 (OR 1.56, 95%CI 1.10-2.21), @entity5600 , @entity13756 (OR 1.27, 95%CI 1.05-1.54), @entity1507 (OR 1.60, 1.03-2.49) and @entity8875 (OR 1.22, 95%CI 1.01-1.48) concentrations but not @entity3494 , pesticides, @entity11572 , @entity28728 , @entity9436 , and polyfluorinated compounds. Moreover, @entity1 who reported difficulties in following conversation with background noise had higher levels of urinary @entity11721 concentrations (OR 1.17, 1.00-1.36). CONCLUSIONS: Urinary heavy metals, @entity5600 , @entity13756 , @entity1507 , @entity8875 , @entity9436 , and polyfluorinated compounds were associated with the adult hearing disturbance, although the causality cannot be established. Elimination of these environmental chemicals might need to be considered in future environmental health policy and health intervention programs.

title: Urinary heavy metals, @entity5600 , @entity13756 , XXXX , @entity8875 , @entity9436 , and polyfluorinated compounds are associated with adult hearing disturbance: USA NHANES, 2011-2012.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'people']

entities_list: @entity8875 :: ('MESH:C031760', 'Chemical') :: ['thiocyanate']

entities_list: @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate']

entities_list: @entity9436 :: ('MESH:D006838', 'Chemical') :: ['hydrocarbons']

entities_list: @entity5600 :: ('CHEBI:26092', 'Chemical') :: ['phthalates']

entities_list: @entity9756 :: ('MESH:D013324', 'Chemical') :: ['strontium']

entities_list: @entity13756 :: ('MESH:C494474', 'Chemical') :: ['perchlorate']

answer: @entity1507 :: (CHEBI:48107,Chemical) :: ['nitrate']


abstract: Importance: Psoriasis is a risk factor for @entity308 . @entity308 may also trigger or exacerbate @entity1569 . The relationship between @entity1569 and @entity308 , however, remains to be fully explored. Objective: To investigate the association between @entity1569 and @entity308 in the US population. Design, Setting, and @entity1 : Population-based study using @entity1 in the National Health and Nutrition Examination Survey from 2009 through 2012. Main Outcomes and Measures: Diagnosis of @entity308 based on the @entity1 Health Questionnaire-9. Results: We identified 351 (2.8%) cases of @entity1569 and 968 (7.8%) cases of @entity308 among 12   382 US citizens included in our study. Fifty-eight (16.5%) @entity1 with @entity1569 met criteria for a diagnosis of @entity308 . The mean (SD) @entity1 Health Questionnaire-9 score was significantly higher among @entity1 with a history of @entity1569 than those without @entity1569 (4.54 [5.7] vs 3.22 [4.3], P   <   .001). Psoriasis was significantly associated with @entity308 , even after adjustment for sex, age, race, body mass index, physical activity, smoking history, @entity285 use, history of @entity583 ( @entity583 ), history of @entity64 , and history of @entity6 (OR, 2.09 [95% CI, 1.41-3.11], P   <   .001). Interaction term analyses involving @entity1 with a history of both @entity1569 and a cardiovascular event, specifically @entity583 or @entity64 , did not reveal a synergistically increased risk of @entity308 ( @entity1569 and @entity583 : OR, 1.09 [95% CI, 0.28-3.60], P   =   .91; @entity1569 and @entity64 : OR, 0.67 [95% CI, 0.12-3.66], P   =   .63). In adjusted multivariable models, the risk of @entity308 was not significantly different between @entity1 with limited vs extensive @entity1569 (OR, 0.66 [95% CI, 0.18-2.44], P   =   .53). Conclusions and Relevance: Self-reported history of @entity1569 was independently associated with @entity308 as assessed by a validated screening tool, even when controlling for comorbidities. History of cardiovascular event did not modify the risk of @entity308 for @entity1 with @entity1569 . The severity of @entity1569 was unrelated to the risk of @entity308 . Therefore, all @entity1 with @entity1569 , regardless of severity, may be at risk for @entity308 .

title: Psoriasis and the Risk of XXXX in the US Population: National Health and Nutrition Examination Survey 2009-2012.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'Participants', 'Patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression', 'major depression']

entities_list: @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

answer: @entity308 :: (MESH:D003866,Disease) :: ['Depression']


abstract: BACKGROUND: Ineffective esophageal motility (IEM) is associated with @entity354 , but its natural history is unclear. We evaluated @entity1 undergoing repeat esophageal high resolution manometry (HRM) for symptomatic presentations after antireflux surgery (ARS) to understand the progression of IEM. METHODS: @entity1 with repeat HRM after ARS were included. Ineffective esophageal motility was diagnosed if >= 5 sequences had distal contractile integral (DCI) <450 mmHg cm s. Augmentation of DCI following @entity1282 ( @entity1282 ) was assessed. The esophagogastric junction (EGJ) was interrogated using the EGJ contractile integral (EGJ-CI). Esophageal motor function was compared between @entity1 with and without IEM. KEY RESULTS: Sixty-eight @entity1 (53.9    1.8 years, 66.2% female) had pre- and post-ARS HRM studies 2.1    0.19 years apart. Esophagogastric junction-CI augmented by a mean of 26.3% following ARS. Four IEM phenotypes were identified: 14.7% had persistent IEM, 8.8% resolved IEM after ARS, 19.1% developed new IEM, and 57.4% had no IEM at any point. @entity1 with IEM had a lower DCI pre- and post-ARS, lower pre-ARS EGJ CI, and lower pre-ARS-integrated relaxation pressure (p  <= 0.02 for all comparisons); presenting symptoms and other EGJ metrics were similar (p >=  0.08 for all comparisons). The IEM phenotypes could be predicted by @entity1282 DCI response patterns (p = 0.008 across groups); @entity1 with persistent IEM had the least DCI augmentation (p = 0.007 compared to no IEM), while those who resolved IEM had DCI augmentation comparable to no IEM (p = 0.08). CONCLUSIONS _ INFERENCES: Distinct phenotypes of IEM exist among symptomatic reflux @entity1 following ARS. Provocative testing with @entity1282 may help identify these phenotypes pre-ARS.

title: Ineffective esophageal motility phenotypes following fundoplication in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['MRS', 'multiple rapid swallows']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['reflux disease']

answer: @entity354 :: (MESH:D005764,Disease) :: ['gastroesophageal reflux disease']


abstract: BACKGROUND: Among the percutaneous procedures for the treatment of @entity4254 , percutaneous anhydrous @entity653 rhizolysis (PRGR) and radiofrequency (RF) ablation of @entity4254 have stood the test of time. OBJECTIVE: A prospective study was conducted to compare PRGR and RF ablation techniques in @entity1 with @entity4254 in terms of (1) efficacy of @entity158 relief, (2) duration of @entity158 relief and (3) side effects. METHODS: All @entity1 presenting to our @entity158 clinic for the first time for the treatment of @entity4254 were enrolled to receive either PRGR or RF ablation; the treatment was chosen by the @entity1 . Demographic data, magnetic resonance imaging scan, relevant medical disease, amount of anhydrous @entity653 , lesion temperature, and total duration of RF were noted. The presence or absence of cerebrospinal fluid egress, immediate @entity158 relief, duration of @entity158 -free period, need for repeat injection or additional peripheral nerve block, and recurrence of @entity158 were also noted. The degree of @entity158 relief was recorded every 3 months. Any complications during the procedure and side effects were also recorded. RESULTS: Seventy-nine @entity1 underwent either PRGR (n = 40) or RF thermocoagulation (n = 39). A total of 23 @entity1 (58.9%) in the PRGR group and 33 @entity1 (84.6%) in the RF group experienced excellent @entity158 relief. The mean duration of excellent @entity158 relief in the PRGR and RF groups was comparable. By the end of the study period, 39.1% @entity1 in the PRGR group and 51.5% @entity1 in the RF group experienced recurrence of @entity158 . CONCLUSION: Both PRGR and RF techniques can achieve acceptable @entity158 relief with minimal side effects.

title: Comparative evaluation of percutaneous retrogasserian @entity653 rhizolysis and radiofrequency thermocoagulation techniques in the management of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4254 :: ('MESH:D014277', 'Disease') :: ['trigeminal neuralgia']

entities_list: @entity653 :: ('MESH:D005990', 'Chemical') :: ['glycerol']

answer: @entity4254 :: (MESH:D014277,Disease) :: ['trigeminal neuralgia']


abstract: BACKGROUND TO THE STUDY: Prisoners tend to be marginalized and deprived of the rights and privileges that other citizens in the community enjoy. Their separation from families, adverse effects on health of prison environment, and the uncertainty about the future place a great psychological burden on them which can lead to the development of @entity1032 . AIMS AND OBJECTIVES: The aim of this study was to determine the prevalence of @entity146 morbidity ( @entity308 and @entity148 ) and the associated factors among a sample of the prison inmates. MATERIALS AND METHOD: The study was descriptive and cross-sectional in design; it was conducted in a medium security prison in Benin City, Nigeria. @entity1 were interviewed with the Self-Reporting Questionnaire-20, the Hospital Anxiety and @entity308 Scale, and a socio-demographic questionnaire. Two hundred and fifty-two prisoners who were selected by systematic sampling techniques participated in the study and the data were analyzed using the 16th version of the SPSS with the statistical level of significance set at p   <   0.05. Data were presented in tables; frequencies and percentages were calculated. Chi-square and logistic regression statistical tests were performed to determine variables that have relationship with @entity146 morbidity. RESULTS: The mean age of the respondents was 33.6 years (SD        9.29), and the majority of the respondents (43.7%) were in the age range 21-30 years. The prevalence of general @entity146 morbidity (SRQ-20 caseness) was 80.6%, while 72.6% and 77.8% were found to be positive for @entity308 and @entity148 symptoms respectively on the HADS. Overall, 84.5% of the respondents had at least one type of @entity146 morbidity. Age, marital status, self-reported physical and mental health, previous @entity1032 , @entity159 , prison accommodation, prison meal, and health care services were found to be significantly associated with @entity308 , @entity148 or general @entity146 morbidity. Self-reported poor current mental health was the only variable that predicted all the three types of @entity146 morbidity. CONCLUSION: Prisoners in this study, and as in previous reports, had high prevalence rates of @entity146 morbidity. Thus, prisoners have a need for regular @entity146 screening and treatment. The consequences of untreated @entity146 morbidity and the need for improved health care services and infrastructure in the prison were discussed.

title: Prevalence and correlates of XXXX and @entity148 in a sample of inmates in a Nigerian prison.

entities_list: @entity1 :: ('9606', 'Species') :: ['Participants']

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental illness']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity159 :: ('MESH:D013226', 'Disease') :: ['imprisonment status']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depression']


abstract: Reduced cell-cell adhesion allows malignant epithelial cells to invade the basal membrane and penetrate the stroma. This implies the potential of the cells to escape from the @entity5 as well as spreading ability. Herein, we investigated the effects of @entity18789 (LA), a @entity1176 agonistic analogue, alone or in combination with @entity586 ( @entity587 ), on the expression of molecules involved in cell adhesion ( @entity5962 , @entity6076 , a-, b- and y-catenin) or in migration/invasion ( @entity1916 , CD44v6 and @entity5689 ) in @entity342 -sensitive (LNCaP) and -insensitive (PC-3) @entity263 (CaP) cells. We demonstrated by immunoblotting that, in LNCaP cells, molecules present in the adherens junctions ( @entity5962 , a-, b- and y-catenin) were expressed, while a-catenin was absent in PC-3 cells which expressed @entity6076 and @entity1916 . In LNCaP cells, no changes in @entity5962 levels were produced by 10(-9) M @entity587 while LA (10(-11) or 10(-6) M) up-regulated the protein level (up to 26-30% after 48 h). In the same cells, b- and y-catenin expression was enhanced either by @entity587 (24 and 20%, respectively) or LA (up to 18 and 40%, respectively), while a-catenin was not affected. Antagonistic effects were consistently observed between @entity587 and LA when the two hormones were jointly administered to the cells. Consistent results were obtained by immunocytochemistry. Co-immunoprecipitation analysis, used to verify the integrity of the LNCaP cell adhesion complex, demonstrated the association of @entity5962 with catenins. In PC-3 cells, adhesion molecule expression, analyzed by immunoblotting, was unaffected by LA, while a down-regulation of @entity1916 (up to 28%) was observed after 24 h of treatment but which did not hold up over time (48-144 h). Our findings demonstrate the efficacy of LA in upregulating @entity5962 , b- and y-catenin in LNCaP cells. This effect, that may be considered as another aspect of the direct antitumor activity of the @entity1176 analogue in hormone-dependent CaP cells, may contribute to maintenance/restoration of the normal tissue architecture counteracting the @entity5 cell spreading tendency.

title: @entity18789 affects adhesion molecule expression in human XXXX cells.

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity586 :: ('MESH:D013196', 'Chemical') :: ['dihydrotestosterone']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor']

entities_list: @entity18789 :: ('CHEBI:63597', 'Chemical') :: ['leuprorelin acetate']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: The sigma-1 receptors bind diverse kinds of psychoactive compounds, including @entity2072 , and translocate upon stimulation by these compounds. However, the exact intracellular localization and dynamics of sigma-1 receptors have been unclear. We recently found that sigma-1 receptors specifically localize on @entity165 -enriched loci on the endoplasmic reticulum (ER) membrane that function as neutral lipid storage sites (i.e., ER lipid droplets or ER-LDs) from which neutral lipids bud out to form cytosolic lipid droplets. By combining immunocytochemistry and real-time monitoring of enhanced yellow fluorescent protein (EYFP)-tagged sigma-1 receptors (Sig-1R-EYFP) in living cells, we characterized the @entity37021 translocation in this study. @entity12586 , a selective @entity37021 agonist, causes a significant decrease of sigma-1 receptors in ER-LDs and a diffused distribution of sigma-1 receptors over the entire endoplasmic reticulum reticular network in @entity19 cells. In the presence of @entity37021 agonists, Sig-1R-EYFP move out from ER-LDs and slide along the endoplasmic reticulum network toward nuclear envelope and the @entity527 . Fluorescence recovery after photobleaching analysis demonstrates that Sig-1R-EYFP on endoplasmic reticulum reticular network are highly mobile compared with those in ER-LDs. A sucrose gradient fractionation study shows that @entity12586 shifts sigma-1 receptors from ER-LD membranes to higher density membranes. These results indicate that sigma-1 receptors localize on ER-LDs and upon stimulation translocate on continuous endoplasmic reticulum reticular network toward peripheries of cells. Because sigma-1 receptors specifically target ER lipid storage sites and compartmentalize neutral lipids therein, these results suggest that sigma-1 receptors' dynamic translocation might affect lipid transport and distribution in neuronal cells.

title: Intracellular dynamics of sigma-1 receptors (sigma(1) binding sites) in XXXX cells.

entities_list: @entity12586 :: ('MESH:D010423', 'Chemical') :: ['(+)-pentazocine', '(+)-Pentazocine']

entities_list: @entity527 :: ('MESH:D058225', 'Disease') :: ['tip of neurites']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity19 :: (10090,Species) :: ['NG108-15']


abstract: We measured the changes during operation in seven markers of coagulation in a prospective series of 84 @entity1 with @entity174 of the tibia or femur who were undergoing reamed intramedullary nailing. All @entity1 were also continually monitored using transoesophageal echocardiography to assess @entity236 . In a subset of 40 @entity1 , intraoperative cardiopulmonary function was monitored, using pulmonary and systemic arterial catheterisation. The procedure produced a significant increase in prothrombin time, activated partial thromboplastin time, the level of prothrombin fragments @entity6343 and D-dimers, and a decrease in the @entity2002 level, suggesting activation of both the coagulation and fibrinolytic pathways. There was evidence of both platelet hyper-reactivity and depletion, as estimated by an increase in @entity4938 levels and a decrease in the platelet count. In the @entity1 who had invasive monitoring there was an incremental increase in mean pulmonary arterial pressure, with the changes being greatest during insertion of the guide-wire and reaming. The change in markers of coagulation, pulmonary artery pressure and arterial @entity26 partial pressures correlated with the intraoperative @entity887 response. Greater changes in these parameters were observed during stabilisation of @entity174 and in those @entity1 in whom surgery had been delayed for more than 48 hours. Seven @entity1 with @entity174 developed more severe @entity519 episodes during reaming, which were associated with significantly greater arterial hypoxaemia, a fall in the right ventricular ejection fraction and an increase in the mean pulmonary artery pressure, pulmonary capillary wedge pressure, central venous pressure and the pulmonary vascular resistance index. These changes suggested that the @entity1 had transient intraoperative right heart strain. Eight @entity1 developed significant postoperative respiratory compromise. They all had severe intraoperative @entity887 responses and, in the three who had invasive monitoring, there was a significantly greater increase in pulmonary artery pressure and alveolar-arterial @entity26 gradient, and a fall in the ratio of arterial partial pressure of @entity26 to the inspired @entity26 concentration. Operative delay, @entity954 and the scores for the severity of the coagulative and @entity887 responses were predictive of the development of @entity260 on univariate logistic regression analysis. On multivariate analysis, however, only the @entity887 and coagulative scores were significant independent predictors of @entity1576 .

title: The coagulative and cardiorespiratory responses to reamed intramedullary nailing of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'pathological fractures']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative respiratory complications']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory complications']

entities_list: @entity954 :: ('MESH:D016063', 'Disease') :: ['intraoperative paradoxical embolisation']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['marrow embolism']

entities_list: @entity4938 :: ('5473', 'Gene') :: ['beta-thromboglobulin']

answer: @entity174 :: (MESH:D050723,Disease) :: ['isolated fractures']


abstract: Granule cell (GC) neurogenesis in the dentate gyrus (DG) does not always proceed normally. After severe @entity410 (e.g., @entity159 [ @entity159 ]) and some other conditions, newborn GCs appear in the hilus. Hilar ectopic GCs (EGCs) can potentially provide insight into the effects of abnormal location and @entity410 on GC development. Additionally, hilar EGCs that develop after @entity159 may contribute to epileptogenesis and @entity73 that follow @entity159 . Thus, it is critical to understand how EGCs differ from normal GCs. Relatively little morphometric information is available on EGCs, especially those restricted to the hilus. This study quantitatively analyzed the structural morphology of hilar EGCs from adult male @entity35 several months after @entity2134 -induced @entity159 , when they are considered to have chronic @entity302 . Hilar EGCs were physiologically identified in slices, intracellularly labeled, processed for light microscopic reconstruction, and compared to GC layer GCs, from both the same post- @entity159 tissue and the NeuroMorpho database (normal GCs). Consistently, hilar EGC and GC layer GCs had similar dendritic lengths and field sizes, and identifiable apical dendrites. However, hilar EGC dendrites were topologically more complex, with more branch points and tortuous dendritic paths. Three-dimensional analysis revealed that, remarkably, hilar EGC dendrites often extended along the longitudinal DG axis, suggesting increased capacity for septotemporal integration. Axonal reconstruction demonstrated that hilar EGCs contributed to mossy fiber sprouting. This combination of preserved and aberrant morphological features, potentially supporting convergent afferent input to EGCs and broad, divergent efferent output, could help explain why the hilar EGC population could impair DG function.

title: Morphometry of hilar ectopic granule cells in the XXXX .

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairments']

entities_list: @entity2134 :: ('MESH:D010862', 'Chemical') :: ['pilocarpine']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity159 :: ('MESH:D013226', 'Disease') :: ['status epilepticus', 'SE']

answer: @entity35 :: (10116,Species) :: ['rat']